Following audit of its new injectable facility at Karakhadi
Alembic Pharmaceuticals has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at the company's New Injectable Facility (F-3) at Karakhadi during the period from 28 January 2021 to 5 February 2021, indicating that the USFDA finds the responses to their observations to be adequate. USFDA has also indicated that a compliance verification would be performed during re-inspection of the said Facility in the next review cycle.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
